



2-17-2017

Recurrent rearrangements of the Myb/SANT-like DNA-binding domain containing 3 gene (MSANTD3) in salivary gland acinic cell carcinoma

Nicholas Barasch

Xue Gong

Kevin A. Kwei

Sushama Varma

Jewison Biscocho

See next page for additional authors

Follow this and additional works at: <https://scholarlycommons.pacific.edu/dugoni-facarticles>

 Part of the [Dentistry Commons](#)

Recommended Citation

Barasch N, Gong X, Kwei KA, Varma S, Biscocho J, Qu K, et al. (2017) Recurrent rearrangements of the Myb/SANT-like DNA-binding domain containing 3 gene (MSANTD3) in salivary gland acinic cell carcinoma. PLoS ONE 12(2): e0171265. <https://doi.org/10.1371/journal.pone.0171265>

This Article is brought to you for free and open access by the Arthur A. Dugoni School of Dentistry at Scholarly Commons. It has been accepted for inclusion in Dugoni School of Dentistry Faculty Articles by an authorized administrator of Scholarly Commons. For more information, please contact mgibney@pacific.edu.

Authors

Nicholas Barasch, Xue Gong, Kevin A. Kwei, Sushama Varma, Jewison Biscocho, Kunbin Qu, Nan (Tori) Xiao, Joseph S. Lipsick, Robert J. Pelham, Robert B. West, and Jonathan R. Pollack

RESEARCH ARTICLE

Recurrent rearrangements of the Myb/SANT-like DNA-binding domain containing 3 gene (*MSANTD3*) in salivary gland acinic cell carcinoma

Nicholas Barasch¹, Xue Gong¹, Kevin A. Kwei^{2aa}, Sushama Varma¹, Jewison Biscocho¹, Kunbin Qu^{2ab}, Nan Xiao³, Joseph S. Lipsick¹, Robert J. Pelham^{2ac}, Robert B. West^{1*}, Jonathan R. Pollack^{1*}


1 Department of Pathology, Stanford University School of Medicine, Stanford, California, United States of America, **2** Genomic Health, Redwood City, California, United States of America, **3** Arthur A. Dugoni School of Dentistry, University of the Pacific, San Francisco, California, United States of America

^{aa} Current address: Pharmacyclics, Sunnyvale, California, United States of America

^{ab} Current address: OncoMed Pharmaceuticals, Redwood City, California, United States of America

^{ac} Current address: Amgen, South San Francisco, California, United States of America

* rbwest@stanford.edu (RBW); pollack1@stanford.edu (JRP)



OPEN ACCESS

Citation: Barasch N, Gong X, Kwei KA, Varma S, Biscocho J, Qu K, et al. (2017) Recurrent rearrangements of the Myb/SANT-like DNA-binding domain containing 3 gene (*MSANTD3*) in salivary gland acinic cell carcinoma. PLoS ONE 12(2): e0171265. doi:10.1371/journal.pone.0171265

Editor: Chandan Kumar-Sinha, University of Michigan, UNITED STATES

Received: August 27, 2016

Accepted: January 17, 2017

Published: February 17, 2017

Copyright: © 2017 Barasch et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: RNA-seq reads are available at GEO (accession GSE76354). The URL is <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE76354>.

Funding: The Stanford authors (NB, XG, SV, JB, JSL, RBW, JRP) were funded by the Stanford University Department of Pathology, and by the NIH/NCI (R01 CA128836 to JSL); those funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The Genomic Health authors (KAK,

Abstract

Pathogenic gene fusions have been identified in several histologic types of salivary gland neoplasia, but not previously in acinic cell carcinoma (AcCC). To discover novel gene fusions, we performed whole-transcriptome sequencing surveys of three AcCC archival cases. In one specimen we identified a novel *HTN3-MSANTD3* gene fusion, and in another a novel *PRB3-ZNF217* gene fusion. The structure of both fusions was consistent with the promoter of the 5' partner (*HTN3* or *PRB3*), both highly expressed salivary gland genes, driving overexpression of full-length *MSANTD3* or *ZNF217*. By fluorescence *in situ* hybridization of an expanded AcCC case series, we observed *MSANTD3* rearrangements altogether in 3 of 20 evaluable cases (15%), but found no additional *ZNF217* rearrangements. *MSANTD3* encodes a previously uncharacterized Myb/SANT domain-containing protein. Immunohistochemical staining demonstrated diffuse nuclear *MSANTD3* expression in 8 of 27 AcCC cases (30%), including the three cases with *MSANTD3* rearrangement. *MSANTD3* displayed heterogeneous expression in normal salivary ductal epithelium, as well as among other histologic types of salivary gland cancer though without evidence of translocation. In a broader survey, *MSANTD3* showed variable expression across a wide range of normal and neoplastic human tissue specimens. In preliminary functional studies, engineered *MSANTD3* overexpression in rodent salivary gland epithelial cells did not enhance cell proliferation, but led to significant upregulation of gene sets involved in protein synthesis. Our findings newly identify *MSANTD3* rearrangement as a recurrent event in salivary gland AcCC, providing new insight into disease pathogenesis, and identifying a putative novel human oncogene.

KQ, RJP) were funded by Genomic Health, whose interest had been in developing robust methods for RNAseq analysis of FFPE specimens; Genomic Health (the funders) had no other role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of the authors are articulated in the 'author contributions' section.

Competing interests: We have the following interests: Kevin A. Kwei, Kunbin Qu and Robert J. Pelham were employed by Genomic Health. The study represents a collaboration between Stanford University and Genomic Health, the latter having had an interest in developing robust methods for RNAseq analysis from FFPE specimens. No patents have been filed, and no resultant products are in development. The affiliation with Genomic Health does not alter our adherence to PLOS ONE policies on sharing data and materials.

Introduction

In cancers, chromosomal translocations and rearrangements can create gene fusions, resulting in the effective overexpression of full-length cancer genes or producing chimeric oncoproteins [1, 2]. Gene fusions were originally considered hallmarks of hematopoietic and mesenchymal cancers, but more recently have been reported in a wide range of epithelial cancer types [2]. Identifying and characterizing gene fusions have provided new molecular insight into disease pathogenesis. Moreover, gene fusions have refined the diagnosis and classification of cancers, and have proven to be effective targets for molecularly-directed therapy. Examples include the classic *BCR-ABL* fusion in chronic myelogenous leukemia [3], and more recently, *EML4-ALK* in lung cancer [4].

Salivary gland neoplasms comprise a collection of at least 30 distinct histopathologic subtypes, including malignant epithelial tumors (e.g. acinic cell carcinoma, adenoid cystic carcinoma, mucoepidermoid carcinoma, and salivary duct carcinoma) and benign epithelial lesions (e.g. pleomorphic adenoma, basal cell adenoma, oncocytoma, myoepithelioma, and Warthin tumor). Developing mainly in the parotid gland, these diagnoses together account for approximately 6% of all head and neck tumors [5]. Over the past years, recurrent gene fusions have been identified in several different salivary gland neoplasms [6–8], including *PLAG1* fusions (most often *CTNNB1-PLAG1*) and *HMGA2* rearrangements in pleomorphic adenoma, *CRTC1-MAML2* fusion in mucoepidermoid carcinoma, *MYB-NFIB* (or *MYBL1-NFIB* [9, 10]) fusion in adenoid cystic carcinoma, *ETV6-NTRK3* fusion in mammary analogue secretory carcinoma of the salivary gland, and *EWSR1-ATF1* fusion in hyalinizing clear cell carcinoma. These fusions, impacting cell signaling pathways and cell-cycle regulation, inform neoplastic mechanisms, provide molecular biomarkers for refined diagnosis, and may suggest new opportunities for therapy. Whether other salivary gland neoplasms also harbor recurrent gene fusions has remained an open question.

Acinic cell carcinoma (AcCC) of the salivary gland is a malignant epithelial neoplasm named for its characteristic acinic cell differentiation [11]. AcCC accounts for approximately 5–11% of all salivary gland carcinomas and is considered as a low-grade malignancy, with a five-year disease-specific survival rate of 91% and a lifetime disease-associated death rate of 16% [12, 13]. Little is known about the pathogenesis of AcCC. Furthermore, ancillary tests and the immunoprofile of AcCC are non-specific and thus, diagnosis is made based primarily on morphologic criteria.

Here, to discover pathogenic gene fusions in AcCC, we performed whole transcriptome analysis of three prototypic cases. We report the identification of a novel gene fusion, *HTN3-MSANTD3*, and recurrent rearrangements of *MSANTD3* in 16% of AcCC. A hitherto unstudied gene, we also here surveyed *MSANTD3* expression across a diverse set of human tissues and neoplasias, and carried out preliminary studies of its function.

Materials and methods

Tissue specimens

Salivary gland acinic cell carcinoma specimens were identified by an electronic search of the Stanford University Department of Pathology archives. In all, we retrieved formalin-fixed paraffin-embedded (FFPE) blocks for 27 cases dating between 1997 and 2014. Hematoxylin and eosin (H&E) stained tissue sections were reviewed by a pathologist (R.B.W) to confirm the diagnosis. Three AcCC cases were used for the RNA-seq studies, while all 27 were incorporated into a tissue microarray (TMA). All existing archived tissue specimens reported in this publication were used with Stanford University Institutional Review Board approval

and HIPAA compliance (with waiver of informed consent based on minimal risk and impracticality).

Transcriptome sequencing (RNA-seq)

RNA-seq of FFPE specimens was done as previously reported [14]. Briefly, FFPE blocks were sectioned (10 μ M thickness), RNA isolated using the Allprep RNA/DNA FFPE kit (Qiagen), and RNA quality verified by Agilent Bioanalyzer. Sequencing libraries (150 bp average insert size) were then prepared from 100 ng of rRNA-depleted RNA using TruSeq RNA Sample Preparation Kit v2 (Illumina), with four indexed libraries loaded per flow-cell lane. Paired-end 75-bp sequencing was carried out on a HiSeq 2000 instrument (Illumina), with the three AcCC libraries yielding 103–110 million sequencing reads. For discovery of gene fusions, evidenced by paired reads mapping to two different genes, and/or reads spanning predicted fusion junctions, we used Chimeriscan [15], TopHat-Fusion [16], SnowShoes-FTD [17], and deFuse [18] software. RNA-seq reads are available at GEO (accession GSE76354). Analysis of publically-available The Cancer Genome Atlas (TCGA) RNA-seq data was done using Wanderer [19], a web-based interactive viewer.

Tissue microarrays

A TMA comprising 27 AcCC cases was constructed as previously described [20], using a manual tissue arrayer (Beecher Instruments). Each case was represented by two 0.6mm cores. Ten additional TMAs, covering other salivary gland tumor diagnoses as well as normal and neoplastic tissues from diverse anatomic sites, and together representing 1495 cases, were previously described [21, 22].

Fluorescence *in situ* hybridization

Identified gene rearrangements were validated in TMA tissue sections by “break apart” FISH assay. Custom FISH probes for the *MSANTD3* locus were generated from bacterial artificial chromosomes (BAC) flanking *MSANTD3*, CTD-3186I20 Cy5 (telomeric) and CTD-2363K7 Cy3 (centromeric) (BACPAC Resources Center, Children’s Hospital Oakland Research Institute). Custom FISH probes for the *ZNF217* locus were CTD-2552P20 Cy5 (telomeric) and CTD-2511E9 Cy3 (centromeric). Break-apart FISH was done as previously described [22]. Briefly, TMA sections (6 μ m) were pretreated with citric acid buffer (pH 6.0). BACs were directly labeled with either Cy5 or Cy3 (GE Healthcare Life Sciences) and then hybridized using Vysis reagents and protocols. Slides were counterstained with 4,6-diamidino 2-phenylindole for microscopy, and images captured using Ariol software (Applied Imaging). For each case, 100 nuclei were evaluated and cases scored positive for rearrangement if ≥ 30 breaks of the two probes were present. Cases with poor FISH probe hybridization were considered unevaluable, and excluded from subsequent analysis.

Immunohistochemistry

MSANTD3 protein expression was evaluated by immunohistochemistry using an anti-*MSANTD3* antibody (LS-C146308, 1:2400 dilution; LifeSpan Biosciences) and peroxidase-based chromogenic staining (EnVision, Dako). All slides were uploaded to the Stanford Tissue Microarray Database [23]. Cores were evaluated for nuclear staining and assigned a score of strong (2), moderate (1), weak (+/-), negative (-), or uninterpretable/missing core (<100 evaluable nuclei). Strong staining was defined as intense staining in >30% or faint staining

in > 70% of nuclei; moderate staining as intense staining in 5–30% or faint staining in 30–70% of nuclei; weak staining as intense staining in 0–5% or faint staining in 10–30% of nuclei; and negative staining as faint staining in <10% of nuclei. Images were independently evaluated using color segmentation software (GemIdent). Briefly, GemIdent was trained to recognize positive and negative nuclei, and a percentage of positive staining was calculated. Since GemIdent could not readily distinguish intensities, the algorithm of < 9% staining was defined as negative, 9–14% as weak, 14–26% as moderate, and >26% as strong. Discrepancies between the manual and automated scores were further reviewed and a final score assigned by the pathologist.

Phylogenetic studies

Conserved protein domains within MSANTD3 were identified by search of NCBI's conserved domain database [24]. Local protein sequence alignments were performed using the Multiple Alignment Construction and Analysis Workbench (MACAW) [25]. Global protein sequence-alignments were performed using ClustalX [26]. A boot-strapped phylogenetic tree was displayed with TreeView [27].

Cell culture studies

SMG-C6 cells, an SV40-immortalized rat submandibular salivary gland acinar cell line [28] (kind gift of Dr. Margarita M. Vasquez, University of Texas Health Science Center at San Antonio), were grown in DMEM/F12 media supplemented as described [29]. NIH-3T3 mouse embryo fibroblasts were obtained from the ATCC and grown in DMEM media supplemented with 10% bovine calf serum. A human C-terminally Myc-tagged MSANTD3 cDNA ORF clone was obtained from Origene (SKU:RC203850), and then subcloned into pLentiCMV-Puro (Addgene #17452) to create pLentiCMV-MSANTD3. pLentiCMV-MSANTD3 or empty vector control was packaged in 293T cells (ATCC) using ViraPower Lenti-viral Packaging Mix (Thermo Fisher Scientific), and then transduced into SMG-C6 cells and selected with 4 µg/ml puromycin. Western blotting was done as previously described [30], using anti-MSANTD3 antibody (LS-C146308, 1:1000 dilution; LifeSpan Biosciences) and anti-Myc antibody (9B11, 1:500 dilution; Cell Signaling). For cell proliferation assays, cells were plated in 6-well plate wells (20,000 cells per well in triplicate) and cell proliferation determined 1, 3 and 5 days later by Wst-1 assay (Roche). For contact-inhibition studies, NIH-3T3 cells were transduced with pLentiCMV-MSANTD3, KRAS(V12) positive-control, or empty vector control as above, and selected in 2 µg/ml puromycin. One million cells were plated per 10 cm dish in triplicate, and 16 days later cells were fixed with methanol, stained with 0.5% crystal violet (in 25% methanol), and then foci ≥ 3 mm counted. For SMG-C6 transcriptome studies, RNA was isolated with RNeasy (Qiagen), and then the TruSeq RNA Sample Preparation Kit v2 (Illumina) used to prepare barcoded-sequence libraries, which were sequenced on an Illumina HiSeq2000 instrument (101bp paired reads) to 36–49 million reads. Reads were aligned to the rat genome using DNAnexus, which also provided reads per kilobase transcript per million mapped reads (RPKM). Non-expressed genes (RPKM<1) were filtered, and gene RPKM ratios (MSANTD3/empty vector) calculated. Differentially-expressed gene sets were then identified using Gene Set Enrichment Analysis (GSEA) [31], with the 'pre-ranked' option and default settings. RNA-seq reads are available at GEO (accession GSE76354).

Results

Transcriptome sequencing identifies novel gene fusions in acinic cell carcinoma

As part of a broader transcriptome survey to discover novel oncogenic gene fusions or mutations in less common cancer diagnoses that are available mainly as archived FFPE tissue blocks [14], here we carried out whole-transcriptome sequencing of three prototypic AcCC cases. Illumina sequencing libraries were constructed from rRNA-depleted total RNA, and Illumina paired-end sequencing (75bp x 2) was done to a depth of 103–110 million reads per case. To discover gene fusions, evidenced by paired sequencing reads mapping to two different genes and/or reads spanning predicted fusion junctions, we used four different software tools: Chimeriscan [15], TopHat-Fusion [16], SnowShoes-FTD [17], and deFuse [18]. All four algorithms identified a total of two fusion genes, both novel, and one in each of two different AcCC cases.

The first novel chimeric transcript resulted from fusion of noncoding exon 1 of *Histatin 3* (*HTN3*; cytoband 4q13.3) to exon 2 (the first coding exon) of *Myb/SANT-like DNA-binding domain contain 3* (*MSANTD3*; cytoband 9q31.1) (Fig 1A). The fusion junction was supported by 51 junction-spanning reads (with 28 unique reads; S1 Fig). Consequent to the rearrangement, the promoter of a highly-expressed salivary gland gene, the microbial peptide precursor *HTN3* [32], ostensibly drives overexpression of *MSANTD3*, an uncharacterized protein harboring a Myb/SANT-like domain characteristic of the MYB oncoprotein and SANT family proteins [33].

The second chimera resulted from fusion of exon 2 of *Proline-rich protein BstNI subfamily 3* (*PRB3*; cytoband 12p13.2) to exon 2 (the first coding exon) of *Zinc finger protein 217* (*ZNF217*; cytoband 20q13.2) (Fig 1B). The fusion junction was supported by 78 junction-spanning reads (with 36 unique reads; S2 Fig). The rearrangement results in the promoter of another highly-expressed salivary gland gene, *PRB3* [34], possibly driving overexpression of *ZNF217*, a reported oncoprotein in several cancer types [35]. However, the start codon (ATG) of *ZNF217* is out of frame relative to the normal *PRB3* open reading frame (Fig 1B), and therefore generation of *ZNF217* protein would necessitate internal initiation of translation.

FISH analysis reveals recurrent *MSANTD3* rearrangement in acinic cell carcinoma

To validate *MSANTD3* rearrangement in the index case, and to identify possible *MSANTD3* rearrangements in additional AcCC cases, we developed a ‘break-apart’ FISH assay. In this assay, differentially fluorescently-labeled FISH probes flanking the *MSANTD3* locus would appear co-localized in normal interphase nuclei, but physically-separated in nuclei harboring allelic rearrangement at the locus. We carried out break-apart FISH on a tissue microarray comprising 27 different AcCC cases, including the three cases evaluated by RNA-seq. In all, 3 of the 20 evaluable cases (including the index case) exhibited break-apart rearrangement of *MSANTD3* locus (Table 1 and Fig 2A–2C), validating the rearrangement in the index case, and estimating the recurrence rate to be 15%. In all three FISH-positive cases, the rearrangement was heterozygous (i.e. affecting only one *MSANTD3* allele), consistent with a dominantly acting oncogene. A fourth AcCC case showed isolated loss of the telomeric FISH probe (downstream of *MSANTD3*) (Table 1), a finding with uncertain expected impact on *MSANTD3* expression.

We developed an analogous ‘break-apart’ FISH assay for the *ZNF217* locus. In all, 13 of the 27 cases were evaluable (i.e. sufficient FISH hybridization signal), and only the index case




Fig 1. Novel genes fusions in acinic cell carcinoma. (A) Predicted structure of the *HTN3-MSANTD3* fusion gene. Exon 1 (non-coding) of *HTN3* is fused to the exon 2 (first coding exon) of *MSANTD3*, leading to predicted overexpression of full-length *MSANTD3* protein (translation start site is indicated). Fusion junction-spanning sequence reads are shown in [S1 Fig](#). (B) Predicted structure of the *PRB3-ZNF217* gene fusion. Here, exon 2 (coding) of *PRB3* is fused to exon 2 (first coding) of *ZNF217*, possibly leading to the overexpression (by internal initiation of translation) of full-length *ZNF217* protein. Fusion junction-spanning sequence reads are shown in [S2 Fig](#).

doi:10.1371/journal.pone.0171265.g001

scored positive for *ZNF217* (heterozygous) locus rearrangement ([Fig 2D](#)). Thus, while we validated rearrangement in the index case, we did not find evidence for recurrent rearrangement. As such, our subsequent studies focused on the recurrent *MSANTD3* rearrangement.

MSANTD3 is highly expressed in a subset of acinic cell carcinomas

In the index case, the *HTN3* promoter ostensibly drives the overexpression of a chimeric transcript encoding full-length *MSANTD3* protein. To evaluate *MSANTD3* protein expression, we carried out immunohistochemistry on the above TMA. Of 27 AcCC cases, 8 (30%) were strongly positive for *MSANTD3* diffuse nuclear-staining (the expected cellular compartment for Myb/SANT domain-containing proteins) ([Table 1](#) and [Fig 2E–2G](#)). The 8 IHC strongly-positive cases included all 3 cases with *MSANTD3* rearrangement, a statistically-meaningful enrichment ($P = 0.02$; two-tailed Fisher’s exact test). Also noteworthy, 7 of the 27 AcCC cases

Table 1. Acinic cell carcinoma cases.

Case ^a	MSANTD3 FISH	MSANTD3 IHC score	ZNF217 FISH	RNA-seq fusion	Lymphocytic infiltrate ^b
1	BREAK APART	Strong	Normal	<i>HTN3-MSANTD3</i>	No
2	BREAK APART	Strong			No
3	BREAK APART	Strong			No
4	Normal	Strong			YES
5	Normal	Strong			YES
6	Normal	Strong			No
7		Strong			No
8	Not scorable	Strong	BREAK APART	<i>PRB3-ZNF217</i>	No
9	Normal	Moderate	Normal		YES
10	Normal	Moderate			YES
11	Normal	Moderate	Normal		No
12	Not scorable	Moderate	Normal		No
13	Normal	Weak	Normal		YES
14	Normal	Weak	Normal		YES
15	Normal	Weak	Normal		YES
16	Normal	Weak	Normal		No
17	Normal	Weak			No
18	Not scorable	Weak	Normal		No
19	Loss of red signal	Negative	Normal		No
20	Normal	Negative	Normal	None identified	No
21	Normal	Negative	Normal		No
22	Normal	Negative			No
23	Normal	Negative			No
24	Normal	Negative			No
25	Not scorable	Negative	Normal		No
26		Negative			No
27		Negative			No

^aOrdered by MSANTD3 IHC score

^bDefined as lymphocytic infiltrate greater than 30%

doi:10.1371/journal.pone.0171265.t001

demonstrated extensive lymphocytic infiltration (a common finding in AcCC; [36]), and all 7 were among the 18 cases that expressed MSANTD3 to some degree (Table 1) ($P = 0.06$, two-tailed Fisher’s exact test); albeit, all 7 cases were FISH-negative for MSANTD3 rearrangement. The meaning of this association is unclear.

MSANTD3 expression varies across other neoplasias of the salivary gland and diverse tissue types

Since MSANTD3 was an unstudied protein, we sought to characterize its expression across a wider array of benign and malignant tissues. Towards this goal, we carried out IHC staining of 11 previously described TMAs, altogether comprising 1293 evaluable cases representing normal and neoplastic tissues of the salivary gland, brain, head and neck, gastrointestinal, cardiovascular, respiratory, immunologic, endocrine, integumentary and musculoskeletal systems. Of these, 258 cases were of salivary origin, and the remaining 1035 cases were from other organ systems and included 235 normal tissues, 70 embryonic tissues, 55 benign or pre-malignant tissues, 40 benign neoplasms and 635 malignant neoplasms.




Fig 2. Evaluation of MSANTD3 rearrangement and protein expression in acinic cell carcinoma tissue sections. (A–C) Break-apart FISH assay of *MSANTD3* locus rearrangement; green FISH probe is flanking centromeric and red FISH probe is flanking telomeric to *MSANTD3*. Note positive rearrangement (evidenced by physically-separated green and red signals, arrows) in AcCC case (A). AcCC case (B) is negative for the rearrangement (i.e., signals co-localize), as is observed in normal salivary gland control (C). (D) Break-apart FISH assay of *ZNF217* rearrangement, confirming the rearrangement in the index case. (E–G) Corresponding *MSANTD3* immunostaining of the above cases. Note the strong nuclear *MSANTD3* staining (E) corresponding to the FISH-positive rearranged specimen.

doi:10.1371/journal.pone.0171265.g002

With respect to the salivary gland tissues (Table 2 and Fig 3A and 3B), *MSANTD3* was expressed in normal salivary gland ductal cells to varying degrees. However, acinar cells were most often entirely negative (24/33 cases), or displayed weak staining (5/33) and at most moderate staining (4/33). While 51% of salivary specimens (benign and malignant) tested were void of any *MSANTD3* staining, strong *MSANTD3* expression was observed in a substantial subset of mucoepidermoid carcinomas (5/25, 20%) and adenosquamous carcinomas (3/5, 60%). FISH performed on 120 of the salivary gland neoplastic cases (other than AcCC) identified no additional *MSANTD3* rearrangements. To exclude the possibility that our *MSANTD3* antibody might cross react with *MYB* (itself rearranged in a subset of salivary gland tumors), IHC-staining for *MYB* was performed and compared with *MSANTD3* staining across 172 cases and no correlation was observed (data not shown).

Beyond the salivary gland (Table 3 and Fig 3C–3P), *MSANTD3* was expressed in a small subset of normal cell types and in many neoplasms. In normal tissues, expression was identified in spermatogonia and early spermatocytes, the parietal cells of stomach, tubular and parietal epithelial cells of the kidney, cortical cells of the adrenal gland, uterine endometrium and the glandular epithelium of the prostate.

Expression in carcinoma was more prominent, with strong expression in multiple gonadally-derived carcinomas, adenocarcinomas of the stomach, lung, pancreas, endometrium, and bladder, as well as, papillary thyroid carcinoma, hepatocellular carcinoma, urothelial carcinoma and a subset of invasive breast cancers. In contrast, *MSANTD3* expression was rarely observed in normal and neoplastic tissues of the brain, head and neck region, esophagus, integument, musculoskeletal system, lymphovascular system, small bowel and large bowel.

Table 2. MSANTD3 immunostaining of salivary gland benign and malignant specimens.

Salivary gland		Immunostaining score (number of cases, %)								Total
		Strong	%	Moderate	%	Weak	%	Negative	%	
Normal	Adult	0	0%	4	12%	5	15%	24	73%	33
	Embryonic	0	0%	0	0%	0	0%	2	100%	2
Benign	Pleomorphic Adenoma	2	4%	5	10%	11	22%	32	64%	50
	Basal Cell Adenoma	0	0%	0	0%	3	33%	6	67%	9
	Monomorphic Adenoma	0	0%	0	0%	0	0%	1	100%	1
	Oncocytoma	1	9%	2	18%	4	36%	4	36%	11
	Oncocystic Hyperplasia	2	67%	0	0%	1	33%	0	0%	3
	Oncocytic Cystadenoma	0	0%	0	0%	1	100%	0	0%	1
	Myoepithelioma	0	0%	0	0%	1	17%	5	83%	6
	Warthin Tumor	1	100%	0	0%	0	0%	0	0%	1
Malignant	<i>AcCC: MSANTD3 Rearrangement</i>	3	100%	0	0%	0	0%	0	0%	3
	<i>AcCC: Normal MSANTD3 FISH</i>	3	18%	3	18%	5	29%	6	35%	17
	<i>AcCC: MSANTD3 FISH not evaluable</i>	2	29%	1	14%	1	14%	3	43%	7
	Adenocarcinoma NOS	1	8%	1	8%	3	23%	8	62%	13
	Adenoid Cystic Carcinoma	3	5%	13	22%	15	25%	28	47%	59
	Adenosquamous Carcinoma	3	60%	0	0%	1	20%	1	20%	5
	Basal Cell Adenocarcinoma	0	0%	0	0%	0	0%	1	100%	1
	Mucoepidermoid	5	20%	8	32%	5	20%	7	28%	25
	Myoepithelial	0	0%	1	20%	1	20%	3	60%	5
	Salivary Duct Carcinoma	1	33%	2	67%	0	0%	0	0%	3
	NOS	0	0%	1	33%	1	33%	1	33%	3
	Total		27	10%	41	16%	58	22%	132	51%

doi:10.1371/journal.pone.0171265.t002

Also, tubularly-derived carcinomas of the kidney did not exhibit staining, an interesting finding considering the prominent expression in normal kidney tubules. Analysis of publicly-available The Cancer Genome Atlas (TCGA) RNA-seq data also showed varied MSANTD3 transcript levels across cancer types, with several exhibiting significantly higher expression in cancer compared to matched normal tissue (S3 Fig).

In addition, because we had stained a large number of breast cancers and had clinical outcome parameters on these specimens, we attempted to identify clinicopathologic correlates. We found no correlation between MSANTD3 expression and ER or HER2 status, nor did we identify a significant correlation with survival ($P = 0.18$, log-rank test).

MSANTD3 protein is highly conserved among tetrapods

Because little was known about MSANTD3, we also examined its evolutionary conservation to infer function and to identify possible relevant model organisms. Human MSANTD3 comprises 275 amino acids, with a predicted molecular weight of 32 kD. A search for conserved protein domains identified only the Myb/SANT domain within the N-terminus (Fig 4A). Analysis of amino acid conservation across species revealed MSANTD3 to be highly conserved in mammals (human), birds (chicken), reptiles (python), and amphibians (frog), but far less conserved in ray-finned fish (cichlid) (Fig 4B–4D). Even more distantly related MSANTD3-like proteins are present in invertebrates (*Ciona*, sea urchin, and fruit fly). There appeared to be no MSANTD3-related gene in nematode worms, plants, fungi, or bacteria. The MSANTD3 homolog in cichlids (bony fish) is about as distant from other vertebrates as is the insect gene. Other fish (e.g. fugu and zebrafish) have even more distantly related genes. Interestingly, the




Fig 3. Representative images of MSANTD3 immunostaining in select tissues. (A) Normal salivary tissue, (B) Mucoepidermoid carcinoma, (C) Normal breast tissue, (D) Invasive breast carcinoma, not otherwise specified, (E) Normal bladder, (F) Urothelial carcinoma, (G) Normal prostate, (H) Normal stomach, (I) Normal kidney, (J) Fetal kidney, (K) Normal liver, (L) Hepatocellular carcinoma, (M) Normal testicle, (N) Seminoma, (O) Testicular atrophy, and (P) Adrenal cortex. Images were acquired at 40x magnification.

doi:10.1371/journal.pone.0171265.g003

coelacanth, a lobe-finned fish that is thought to be related to a common ancestor of all tetrapods [37], has an MSANT3 protein more similar to those of land vertebrates. Furthermore, the vertebrate and coelacanth proteins share homologous regions outside of the N-terminal Myb/SANT domain that are poorly conserved in other species.

MSANTD3 overexpression upregulates genes functioning in protein synthesis

Recurrent rearrangement of *MSANTD3* in AcCC, ostensibly driving overexpression of the full-length MSANTD3 protein, combined with observed overexpression by IHC, strongly suggested an oncogenic driver role in AcCC. To preliminarily characterize potential oncogenic functions, we used lentiviral transduction to engineer MSANTD3 overexpression in cultured cells, first using an immortalized rat submandibular salivary gland acinar cell line model [28], SMG-C6. Overexpression of MSANTD3 in SMG-C6 cells, confirmed by western blot (Fig 5A)

Table 3. MSANTD3 immunostaining across diverse benign and neoplastic tissues.

	Tissue	MSANTD3 strong immunostaining (No. cases)	Total No. cases	% strongly positive
Testis	<i>Normal</i>	14	14	100%
	Atrophic/Immature	0	4	0%
	Seminoma	19	22	86%
	Teratoma	2	3	67%
	Yolk Sac Tumor	4	4	100%
	Embryonal Carcinoma	1	2	50%
	Granulosa Cell Tumor	1	1	100%
	Leydig Cell Tumor	0	1	0%
Adrenal	<i>Normal Cortex</i>	14	22	64%
	Adenoma	1	3	33%
	Adrenocortical Carcinoma	1	2	50%
	Pheochromocytoma	0	2	0%
Bladder	<i>Normal</i>	0	7	0%
	Embryonic	0	2	0%
	Adenocarcinoma	2	3	67%
	Urothelial Carcinoma	3	14	21%
Breast	<i>Normal</i>	0	7	0%
	Invasive Ductal	4	11	36%
	Invasive Lobular	2	3	67%
	Invasive NOS	75	248	30%
Kidney	<i>Normal</i>	11	13	85%
	Embryo	0	5	0%
	Oncocytoma	0	2	0%
	Clear Cell Carcinoma	0	1	0%
	Conventional Carcinoma	0	4	0%
	Papillary Carcinoma	0	4	0%
Liver	<i>Normal</i>	0	11	0%
	Hepatocellular	4	10	40%
Lung	Normal	0	7	0%
	Adenocarcinoma	8	14	57%
Ovary	Normal	0	7	0%
	Mucinous Carcinoma	2	3	67%
	Clear Cell Carcinoma	3	4	75%
	Serous Carcinoma	3	5	60%
Prostate	<i>Normal</i>	3	6	50%
	Adenocarcinoma	7	12	58%
Stomach	<i>Normal</i>	3	10	30%
	Adenocarcinoma	5	7	71%
Thyroid	<i>Normal</i>	0	12	0%
	Papillary Carcinoma	2	5	40%
	Follicular Carcinoma	1	2	50%
Pancreas	<i>Normal</i>	0	3	0%
	Adenocarcinoma	1	2	50%
	Ductal	2	3	67%
Uterus	Endometrium	2	3	67%
	Endometrial Carcinoma	7	11	64%
	Leiomyosarcoma	0	5	0%

doi:10.1371/journal.pone.0171265.t003




Fig 4. MSANTD3 structural domains and phylogenetic conservation. (A) Schematic depiction of MSANTD3 domains, showing the location of the Myb/SANT-like domain within the N-terminus. (B) Schematic depiction of MSANTD3 MACAW sequence alignments across species. Boxes indicate conserved blocks, while the shading indicates pair-wise scores relative to human MSANTD3 with colors indicated in the key. Above, the horizontal black bar indicates the location of the conserved Myb/SANT domain found by NCBI search (Pfam 13873). (C) Actual MACAW alignment within the MYB/SANT region. (D) Phylogenetic tree based on the global alignment made by ClustalX and visualized using Treeview software.

doi:10.1371/journal.pone.0171265.g004

did not enhance cell proliferation (Fig 5B). Nor did overexpression of MSANTD3 in NIH-3T3 mouse embryo fibroblast cells result in lost contact-inhibition (assayed by focus formation; S4 Fig). To explore potential oncogenic phenotypes more broadly, we profiled transcriptomic changes by RNA-seq in SMG-C6 cells overexpressing MSANTD3, compared to empty vector control. By Gene Set Enrichment Analysis, MSANTD3 overexpression led to marked upregulation of multiple gene sets associated with protein synthesis, including ‘ribosome’, ‘peptide chain elongation’, and ‘translation’ (Fig 5C and S1 Table).




Fig 5. MSANTD3 overexpression leads to the upregulation of genes involved in protein synthesis. (A) Overexpression of C-terminally Myc-tagged MSANTD3 in SMG-C6 immortalized rat salivary gland epithelial cells, demonstrated by western blot using anti-MSANTD3 antibody (*left*) and anti-Myc tag antibody (*right*). Note, the observed band runs close to the calculated MW of the tagged protein (36 kD). (B) MSANTD3 overexpression does not enhance cell proliferation, compared to empty vector control, quantified by Wst-1 assay. (C) Transcriptome (RNA-seq) analysis of MSANTD3 overexpression identifies significant upregulation of gene sets associated with protein synthesis. Gene Set Enrichment Analysis (GSEA) of the top gene set ('KEGG Ribosome') is shown; other significant gene sets are listed in [S1 Table](#). Note, the early and positive upswing of the Enrichment profile reflects the early concentration of ribosome genes within the ranked list of genes upregulated by MSANTD3 overexpression (compared to empty vector control).

doi:10.1371/journal.pone.0171265.g005

Discussion

Recurrent chromosomal rearrangements (and the resultant gene fusions) are known to characterize other salivary gland tumors, but have not previously been reported in AcCC. Here, by whole-transcriptome profiling of three AcCC cases, we discovered two novel fusion genes, *HTN-MSANTD3* and *PRB3-ZNF217*, and found that *MSANTD3* locus rearrangements are recurrent events observed in approximately 15% of AcCC cases. Furthermore, in a cell line model, MSANTD3 overexpression led to the upregulation of genes involved in protein synthesis, a cellular process often upregulated in cancer [38].

Notably, both novel fusion genes juxtapose a highly-expressed salivary gland gene (*HTN3* or *PRB3*) to the full-length 3' partner (*MSANTD3* and *ZNF217*, respectively), ostensibly driving the overexpression of a chimeric transcript encoding the full-length 3' fusion partner. For the *MSANTD3* rearrangement, we showed by immunostaining that MSANTD3 protein was in fact highly expressed in all three cases with DNA rearrangement. Though we note that for the other two cases with *MSANTD3* rearrangement, the FFPE tissue blocks were exhausted and so we did not have the opportunity to identify a putative 5' fusion partner, which may or may not

also be *HTN3*. Notably, *MSANTD3* protein was highly expressed in an additional 5 cases (for 30% of all cases), presumably upregulated by some mechanism other than genomic DNA rearrangement.

With respect to the *PRB3-ZNF217* fusion, *ZNF217* is a zinc finger protein, a protein family often functioning in transcriptional regulation through sequence-specific DNA binding [39]. *ZNF217* was first characterized as the 'driver' oncogene amplified at 20q13.2 in breast cancer [40], where it was found to promote cellular immortalization [40]. Since then, *ZNF217* has been implicated in ovarian and other cancer types, where it has been linked to diverse oncogenic phenotypes including cell proliferation, survival, and invasion [35]. Although we have not found *ZNF217* rearrangements in other AcCC cases, and we have not demonstrated *ZNF217* protein expression, given its known oncogenic functions in other cancers it is intriguing to speculate a possible pathogenic role in a subset of AcCC cases.

In contrast, the recurrent nature of *MSANTD3* gene rearrangements provides strong genetic support for its pathogenic role. *MSANTD3* is a previously unstudied gene, named for harboring a protein domain with shared homology to the DNA-binding domains of MYB and SANT-family proteins. *MYB*, the homolog of the avian myeloblastosis viral oncogene, functions in normal hematopoiesis, and deregulated *MYB* expression has been linked with human leukemia [41]. SANT is an acronym for switching-defective protein 3 (Swi3), adaptor 2 (Ada2), nuclear receptor co-repressor (N-CoR), transcription factor (TF)IIIB, with the four proteins (and others since) found to share a conserved 50 amino-acid motif with the MYB DNA-binding domain [33]. SANT domains are often present within subunits of chromatin-remodeling and histone-modifying complexes [42]. It was initially hypothesized that all SANT domains bind directly to DNA to enable their regulatory function. Structural and biochemical evidence for this model has been provided in at least some cases [43–45]. However, it has also been hypothesized that some SANT domains may bind directly to histones rather than to DNA in order to regulate chromatin structure and function [42].

Interestingly, in a recent yeast two-hybrid screen to identify binding partners of methyltransferase enzymes [46], *MSANTD3* (formerly known as C9orf30) was identified as one of many putative binding partners of SUV39H1, itself a histone methyltransferase functioning in establishing heterochromatin [47]. This finding implicates a possible role of *MSANTD3* in chromatin regulation, a function consistent with its having a Myb/SANT-like domain. We also note that the observed immunostaining was predominantly nuclear, also consistent with a role in chromatin dynamics. Nonetheless, detailed mechanistic studies will be necessary to elucidate the protein's normal function.

To further explore *MSANTD3* biology, we carried out a broad immunostaining survey of diverse normal and neoplastic tissues. Within the normal salivary gland, *MSANTD3* generally showed higher expression in ductal compared to acinar cells. *MSANTD3* was also expressed in a subset of other salivary gland neoplasias, though without evidence of locus rearrangement. Other tissues that stained strongly included normal testis and kidney, and glandular tissues including prostate and endometrium. Adenocarcinomas of diverse organ sites showed varied staining, while squamous cell carcinomas, sarcomas, and lymphoid-derived neoplasias were generally void of staining. The expression of *MSANTD3* across diverse tissue types, as well as its protein conservation down to amphibians, suggests an important cellular function(s). Those functions, as well as possible roles in diseases beyond AcCC, remain to be explored.

To further characterize its pathogenic role in AcCC, we overexpressed *MSANTD3* in SMG-C6 immortalized rat salivary gland epithelial cells, a reasonable approximation of a normal cell type equivalent. *MSANTD3* overexpression did not enhance cell proliferation. However, by expression profiling we found that its overexpression led, either directly or indirectly, to marked upregulation of genes involved in translation of mRNA into proteins by ribosomes.

This finding is intriguing because increased protein synthesis is a common feature of cancers [38]. Oncoproteins including PI3-kinases, AKT kinase, ribosomal S6 kinase, and MYC are all thought to act in large part by enhancing ribosome biogenesis and translation, to provide needed new proteins for cell growth and proliferation [48, 49].

Of note, in a recent RNA-seq survey of cancer cell lines, a *XRCC4-MSANTD3* in-frame fusion was reported in SW780 bladder transitional cell carcinoma cells [50] (their Supplementary Table 8). However, that fusion was supported by only two sequencing reads, and the predicted fusion incorporates only the terminal exon of *MSANTD3* and so would be missing the highly-conserved Myb/SANT-like domain, and thus is unlikely to be functional.

Although the exact role(s) of *MSANTD3* in AcCC oncogenesis remain to be determined, it is also intriguing that MYB itself, which of course also harbors a Myb/SANT-like domain, is part of a gene fusion that characterizes a different salivary gland tumor: *MYB-NFIB* in adenoid cystic carcinoma. Perhaps this finding suggests a more general role of Myb/SANT-like DNA-binding domain containing proteins in the normal biology and neoplastic conversion of salivary epithelium.

From a diagnostic standpoint, several salivary gland neoplasias have been found to harbor specific gene fusions that have proven to be useful biomarkers for differential diagnosis [6]. In our study, we have identified *MSANTD3* rearrangements in 15% of AcCC specimens, and in no other salivary gland neoplasias. While its modest frequency in AcCC would limit its overall diagnostic utility, finding *MSANTD3* rearrangement (e.g. by FISH) in a diagnostically challenging case could nonetheless provide support for a diagnosis of AcCC. Whether *MSANTD3* rearrangement and/or overexpression confer a distinct prognosis remains unanswered, and need await studies on larger cohorts with clinical follow up.

In summary, by whole-transcriptome sequencing of archival AcCC cases and validation by FISH, we have discovered novel gene fusions including a recurrent rearrangement of the previously uncharacterized gene *MSANTD3*. Functional studies implicate a role of *MSANTD3* in upregulating translation; however, the normal and tumorigenic mechanisms of this novel putative oncogene await future investigation. Based on our studies, AcCC now joins other salivary gland neoplasias in harboring specific chromosome rearrangements, and may ultimately aid in the diagnosis and understanding of disease pathogenesis.

Supporting information

S1 Fig. *HTN3-MSANTD3* junction-spanning reads. Shown are the 51 sequencing reads spanning the predicted *HTN3-MSANTD3* junction, identified from the Chimeriscan analysis. (PDF)

S2 Fig. *PRB3-ZNF217* junction-spanning reads. Shown are the 78 sequencing reads spanning the predicted *PRB3-ZNF217* junction, identified from the Chimeriscan analysis. (PDF)

S3 Fig. *MSANTD3* transcript levels vary across cancer types. Plots display normalized transcript levels for cancer vs. normal samples, shown for those TCGA cancer types where there are sufficient sample numbers to perform a statistical analysis (tumor vs. normal; Wilcoxon *P*-value indicated). Plots assembled using Wanderer (see [Methods](#)). (PDF)

S4 Fig. *MSANTD3* overexpression does not lead to loss of contact-inhibition (focus formation). (A) Focus formation assay in NIH-3T3 cells transduced with pLenti-CMV-*MSANTD3* (vs. pLenti-CMV empty vector control), or positive control pBABE-KRAS(V12) (vs. pBABE empty vector control). Crystal violet stained foci were manually counted in triplicate 10cm

plates; representative plates shown. **(B)** Graphical display of counted foci. Note, no foci (>3mm) were observed following MSANTD3 overexpression.
(PDF)

S1 Table. Canonical pathway gene sets found enriched by GSEA analysis.
(PDF)

Acknowledgments

We wish to thank members of the Pollack and West labs for helpful discussions, and Dr. Adam Kapelner for his assistance with the creation and use of GemIdent.

Author Contributions

Conceptualization: NB KAK RJP RBW JRP.

Formal analysis: NB XG KQ JSL.

Investigation: NB KAK SV JB.

Resources: NX.

Writing – original draft: NB RBW JRP.

References

1. Mitelman F, Johansson B, Mertens F. The impact of translocations and gene fusions on cancer causation. *Nat Rev Cancer*. 2007; 7(4):233–45. doi: [10.1038/nrc2091](https://doi.org/10.1038/nrc2091) PMID: [17361217](https://pubmed.ncbi.nlm.nih.gov/17361217/)
2. Brenner JC, Chinnaiyan AM. Translocations in epithelial cancers. *Biochim Biophys Acta*. 2009; 1796(2):201–15. Epub 2009/05/02. doi: [10.1016/j.bbcan.2009.04.005](https://doi.org/10.1016/j.bbcan.2009.04.005) PMID: [19406209](https://pubmed.ncbi.nlm.nih.gov/19406209/)
3. Kurzrock R, Kantarjian HM, Druker BJ, Talpaz M. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. *Ann Intern Med*. 2003; 138(10):819–30. Epub 2003/05/21. PMID: [12755554](https://pubmed.ncbi.nlm.nih.gov/12755554/)
4. Hallberg B, Palmer RH. Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. *Nat Rev Cancer*. 2013; 13(10):685–700. Epub 2013/09/26. doi: [10.1038/nrc3580](https://doi.org/10.1038/nrc3580) PMID: [24060861](https://pubmed.ncbi.nlm.nih.gov/24060861/)
5. Stenner M, Klussmann JP. Current update on established and novel biomarkers in salivary gland carcinoma pathology and the molecular pathways involved. *Eur Arch Otorhinolaryngol*. 2009; 266(3):333–41. Epub 2008/12/05. doi: [10.1007/s00405-008-0882-7](https://doi.org/10.1007/s00405-008-0882-7) PMID: [19052760](https://pubmed.ncbi.nlm.nih.gov/19052760/)
6. Stenman G. Fusion oncogenes in salivary gland tumors: molecular and clinical consequences. *Head Neck Pathol*. 2013; 7 Suppl 1:S12–9. Epub 2013/07/04.
7. Bell D, Hanna EY. Salivary gland cancers: biology and molecular targets for therapy. *Curr Oncol Rep*. 2012; 14(2):166–74. Epub 2012/01/17. doi: [10.1007/s11912-012-0220-5](https://doi.org/10.1007/s11912-012-0220-5) PMID: [22246609](https://pubmed.ncbi.nlm.nih.gov/22246609/)
8. Weinreb I. Translocation-associated salivary gland tumors: a review and update. *Adv Anat Pathol*. 2013; 20(6):367–77. Epub 2013/10/12. doi: [10.1097/PAP.0b013e3182a92cc3](https://doi.org/10.1097/PAP.0b013e3182a92cc3) PMID: [24113307](https://pubmed.ncbi.nlm.nih.gov/24113307/)
9. Mitani Y, Liu B, Rao P, Borra V, Zafereo M, Weber RS, et al. Novel MYBL1 gene rearrangements with recurrent MYBL1-NFIB fusions in salivary adenoid cystic carcinomas lacking t(6;9) translocations. *Clin Cancer Res*. 2015. Epub 2015/12/04.
10. Brayer KJ, Frerich CA, Kang H, Ness SA. Recurrent Fusions in MYB and MYBL1 Define a Common, Transcription Factor-Driven Oncogenic Pathway in Salivary Gland Adenoid Cystic Carcinoma. *Cancer Discov*. 2015. Epub 2015/12/04.
11. Godwin JT, Foote FW Jr., Frazell EL. Acinic cell adenocarcinoma of the parotid gland; report of twenty-seven cases. *Am J Pathol*. 1954; 30(3):465–77. Epub 1954/05/01. PMID: [13158522](https://pubmed.ncbi.nlm.nih.gov/13158522/)
12. Hoffman HT, Karnell LH, Robinson RA, Pinkston JA, Menck HR. National Cancer Data Base report on cancer of the head and neck: acinic cell carcinoma. *Head Neck*. 1999; 21(4):297–309. Epub 1999/06/22. PMID: [10376748](https://pubmed.ncbi.nlm.nih.gov/10376748/)
13. Hall DA, Pu RT. Acinic cell carcinoma of the salivary gland: a continuing medical education case. *Diagn Cytopathol*. 2008; 36(6):379–85; quiz 86–7. Epub 2008/05/15. doi: [10.1002/dc.20852](https://doi.org/10.1002/dc.20852) PMID: [18478605](https://pubmed.ncbi.nlm.nih.gov/18478605/)

14. Sweeney RT, McClary AC, Myers BR, Biscocho J, Neahrng L, Kwei KA, et al. Identification of recurrent SMO and BRAF mutations in ameloblastomas. *Nat Genet.* 2014; 46(7):722–5. Epub 2014/05/27. doi: [10.1038/ng.2986](https://doi.org/10.1038/ng.2986) PMID: [24859340](https://pubmed.ncbi.nlm.nih.gov/24859340/)
15. Iyer MK, Chinnaiyan AM, Maher CA. ChimeraScan: a tool for identifying chimeric transcription in sequencing data. *Bioinformatics.* 2011; 27(20):2903–4. doi: [10.1093/bioinformatics/btr467](https://doi.org/10.1093/bioinformatics/btr467) PMID: [21840877](https://pubmed.ncbi.nlm.nih.gov/21840877/)
16. Kim D, Salzberg SL. TopHat-Fusion: an algorithm for discovery of novel fusion transcripts. *Genome Biol.* 2011; 12(8):R72. Epub 2011/08/13. doi: [10.1186/gb-2011-12-8-r72](https://doi.org/10.1186/gb-2011-12-8-r72) PMID: [21835007](https://pubmed.ncbi.nlm.nih.gov/21835007/)
17. Asmann YW, Hossain A, Necela BM, Middha S, Kalari KR, Sun Z, et al. A novel bioinformatics pipeline for identification and characterization of fusion transcripts in breast cancer and normal cell lines. *Nucleic Acids Res.* 2011; 39(15):e100. Epub 2011/05/31. doi: [10.1093/nar/gkr362](https://doi.org/10.1093/nar/gkr362) PMID: [21622959](https://pubmed.ncbi.nlm.nih.gov/21622959/)
18. McPherson A, Hormozdiari F, Zayed A, Giuliany R, Ha G, Sun MG, et al. deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data. *PLoS Comput Biol.* 2011; 7(5):e1001138. Epub 2011/06/01. doi: [10.1371/journal.pcbi.1001138](https://doi.org/10.1371/journal.pcbi.1001138) PMID: [21625565](https://pubmed.ncbi.nlm.nih.gov/21625565/)
19. Diez-Villanueva A, Mallona I, Peinado MA. Wanderer, an interactive viewer to explore DNA methylation and gene expression data in human cancer. *EpiGenetics Chromatin.* 2015; 8:22. Epub 2015/06/27. doi: [10.1186/s13072-015-0014-8](https://doi.org/10.1186/s13072-015-0014-8) PMID: [26113876](https://pubmed.ncbi.nlm.nih.gov/26113876/)
20. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. *Nat Med.* 1998; 4(7):844–7. PMID: [9662379](https://pubmed.ncbi.nlm.nih.gov/9662379/)
21. Nguyen TT, Schwartz EJ, West RB, Warnke RA, Arber DA, Natkunam Y. Expression of CD163 (hemoglobin scavenger receptor) in normal tissues, lymphomas, carcinomas, and sarcomas is largely restricted to the monocyte/macrophage lineage. *Am J Surg Pathol.* 2005; 29(5):617–24. Epub 2005/04/16. PMID: [15832085](https://pubmed.ncbi.nlm.nih.gov/15832085/)
22. West RB, Kong C, Clarke N, Gilks T, Lipsick JS, Cao H, et al. MYB expression and translocation in adenoid cystic carcinomas and other salivary gland tumors with clinicopathologic correlation. *Am J Surg Pathol.* 2011; 35(1):92–9. Epub 2010/12/18. doi: [10.1097/PAS.0b013e3182002777](https://doi.org/10.1097/PAS.0b013e3182002777) PMID: [21164292](https://pubmed.ncbi.nlm.nih.gov/21164292/)
23. Marinelli RJ, Montgomery K, Liu CL, Shah NH, Prapong W, Nitzberg M, et al. The Stanford Tissue Microarray Database. *Nucleic Acids Res.* 2008; 36(Database issue):D871–7. doi: [10.1093/nar/gkm861](https://doi.org/10.1093/nar/gkm861) PMID: [17989087](https://pubmed.ncbi.nlm.nih.gov/17989087/)
24. Marchler-Bauer A, Derbyshire MK, Gonzales NR, Lu S, Chitsaz F, Geer LY, et al. CDD: NCBI's conserved domain database. *Nucleic Acids Res.* 2015; 43(Database issue):D222–6. Epub 2014/11/22. doi: [10.1093/nar/gku1221](https://doi.org/10.1093/nar/gku1221) PMID: [25414356](https://pubmed.ncbi.nlm.nih.gov/25414356/)
25. Schuler GD, Altschul SF, Lipman DJ. A workbench for multiple alignment construction and analysis. *Proteins.* 1991; 9(3):180–90. Epub 1991/01/01. doi: [10.1002/prot.340090304](https://doi.org/10.1002/prot.340090304) PMID: [2006136](https://pubmed.ncbi.nlm.nih.gov/2006136/)
26. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, et al. Clustal W and Clustal X version 2.0. *Bioinformatics.* 2007; 23(21):2947–8. Epub 2007/09/12. doi: [10.1093/bioinformatics/btm404](https://doi.org/10.1093/bioinformatics/btm404) PMID: [17846036](https://pubmed.ncbi.nlm.nih.gov/17846036/)
27. Page RD. TreeView: an application to display phylogenetic trees on personal computers. *Comput Appl Biosci.* 1996; 12(4):357–8. Epub 1996/08/01. PMID: [8902363](https://pubmed.ncbi.nlm.nih.gov/8902363/)
28. Quissell DO, Barzen KA, Gruenert DC, Redman RS, Camden JM, Turner JT. Development and characterization of SV40 immortalized rat submandibular acinar cell lines. *In Vitro Cell Dev Biol Anim.* 1997; 33(3):164–73. Epub 1997/03/01. doi: [10.1007/s11626-997-0137-8](https://doi.org/10.1007/s11626-997-0137-8) PMID: [9112124](https://pubmed.ncbi.nlm.nih.gov/9112124/)
29. Vasquez MM, Mustafa SB, Choudary A, Seidner SR, Castro R. Regulation of epithelial Na⁺ channel (ENaC) in the salivary cell line SMG-C6. *Exp Biol Med (Maywood).* 2009; 234(5):522–31. Epub 2009/02/24.
30. Choi YL, Bocanegra M, Kwon MJ, Shin YK, Nam SJ, Yang JH, et al. LYN is a mediator of epithelial-mesenchymal transition and a target of dasatinib in breast cancer. *Cancer Res.* 2010; 70(6):2296–306. doi: [10.1158/0008-5472.CAN-09-3141](https://doi.org/10.1158/0008-5472.CAN-09-3141) PMID: [20215510](https://pubmed.ncbi.nlm.nih.gov/20215510/)
31. Subramanian A, Kuehn H, Gould J, Tamayo P, Mesirov JP. GSEA-P: a desktop application for Gene Set Enrichment Analysis. *Bioinformatics.* 2007; 23(23):3251–3. doi: [10.1093/bioinformatics/btm369](https://doi.org/10.1093/bioinformatics/btm369) PMID: [17644558](https://pubmed.ncbi.nlm.nih.gov/17644558/)
32. vanderSpek JC, Offner GD, Troxler RF, Oppenheim FG. Molecular cloning of human submandibular histatins. *Arch Oral Biol.* 1990; 35(2):137–43. Epub 1990/01/01. PMID: [2344289](https://pubmed.ncbi.nlm.nih.gov/2344289/)
33. Aasland R, Stewart AF, Gibson T. The SANT domain: a putative DNA-binding domain in the SWI-SNF and ADA complexes, the transcriptional co-repressor N-CoR and TFIIB. *Trends Biochem Sci.* 1996; 21(3):87–8. Epub 1996/03/01. PMID: [8882580](https://pubmed.ncbi.nlm.nih.gov/8882580/)
34. Azen E, Prakobphol A, Fisher SJ. PRB3 null mutations result in absence of the proline-rich glycoprotein GI and abolish *Fusobacterium nucleatum* interactions with saliva in vitro. *Infect Immun.* 1993; 61(10):4434–9. Epub 1993/10/01. PMID: [8406834](https://pubmed.ncbi.nlm.nih.gov/8406834/)

35. Cohen PA, Donini CF, Nguyen NT, Lincet H, Vendrell JA. The dark side of ZNF217, a key regulator of tumorigenesis with powerful biomarker value. *Oncotarget*. 2015. Epub 2015/10/03.
36. Ellis GL, Auclair PL. Tumors of the salivary glands. American Registry of Pathology; Armed Forces Institute of Pathology (US). 2008:Washington, DC: American Registry of Pathology in collaboration with the Armed Forces Institute of Pathology.
37. Amemiya CT, Alfoldi J, Lee AP, Fan S, Philippe H, Maccallum I, et al. The African coelacanth genome provides insights into tetrapod evolution. *Nature*. 2013; 496(7445):311–6. Epub 2013/04/20. doi: [10.1038/nature12027](https://doi.org/10.1038/nature12027) PMID: [23598338](https://pubmed.ncbi.nlm.nih.gov/23598338/)
38. Ruggero D, Pandolfi PP. Does the ribosome translate cancer? *Nat Rev Cancer*. 2003; 3(3):179–92. Epub 2003/03/04. doi: [10.1038/nrc1015](https://doi.org/10.1038/nrc1015) PMID: [12612653](https://pubmed.ncbi.nlm.nih.gov/12612653/)
39. Razin SV, Borunova VV, Maksimenko OG, Kantidze OL. Cys2His2 zinc finger protein family: classification, functions, and major members. *Biochemistry (Mosc)*. 2012; 77(3):217–26. Epub 2012/07/19.
40. Collins C, Rommens JM, Kowbel D, Godfrey T, Tanner M, Hwang SI, et al. Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma. *Proc Natl Acad Sci U S A*. 1998; 95(15):8703–8. PMID: [9671742](https://pubmed.ncbi.nlm.nih.gov/9671742/)
41. Ramsay RG, Gonda TJ. MYB function in normal and cancer cells. *Nat Rev Cancer*. 2008; 8(7):523–34. Epub 2008/06/25. doi: [10.1038/nrc2439](https://doi.org/10.1038/nrc2439) PMID: [18574464](https://pubmed.ncbi.nlm.nih.gov/18574464/)
42. Boyer LA, Latek RR, Peterson CL. The SANT domain: a unique histone-tail-binding module? *Nat Rev Mol Cell Biol*. 2004; 5(2):158–63. Epub 2004/03/26. doi: [10.1038/nrm1314](https://doi.org/10.1038/nrm1314) PMID: [15040448](https://pubmed.ncbi.nlm.nih.gov/15040448/)
43. Grune T, Brzeski J, Eberharter A, Clapier CR, Corona DF, Becker PB, et al. Crystal structure and functional analysis of a nucleosome recognition module of the remodeling factor ISWI. *Mol Cell*. 2003; 12(2):449–60. Epub 2003/10/11. PMID: [14536084](https://pubmed.ncbi.nlm.nih.gov/14536084/)
44. Sharma A, Jenkins KR, Heroux A, Bowman GD. Crystal structure of the chromodomain helicase DNA-binding protein 1 (Chd1) DNA-binding domain in complex with DNA. *J Biol Chem*. 2011; 286(49):42099–104. Epub 2011/10/29. doi: [10.1074/jbc.C111.294462](https://doi.org/10.1074/jbc.C111.294462) PMID: [22033927](https://pubmed.ncbi.nlm.nih.gov/22033927/)
45. Yamada K, Frouws TD, Angst B, Fitzgerald DJ, DeLuca C, Schimmele K, et al. Structure and mechanism of the chromatin remodelling factor ISW1a. *Nature*. 2011; 472(7344):448–53. Epub 2011/04/29. doi: [10.1038/nature09947](https://doi.org/10.1038/nature09947) PMID: [21525927](https://pubmed.ncbi.nlm.nih.gov/21525927/)
46. Weimann M, Grossmann A, Woodsmith J, Ozkan Z, Birth P, Meierhofer D, et al. A Y2H-seq approach defines the human protein methyltransferase interactome. *Nat Methods*. 2013; 10(4):339–42. Epub 2013/03/05. doi: [10.1038/nmeth.2397](https://doi.org/10.1038/nmeth.2397) PMID: [23455924](https://pubmed.ncbi.nlm.nih.gov/23455924/)
47. Rea S, Eisenhaber F, O'Carroll D, Strahl BD, Sun ZW, Schmid M, et al. Regulation of chromatin structure by site-specific histone H3 methyltransferases. *Nature*. 2000; 406(6796):593–9. Epub 2000/08/19. doi: [10.1038/35020506](https://doi.org/10.1038/35020506) PMID: [10949293](https://pubmed.ncbi.nlm.nih.gov/10949293/)
48. Bader AG, Kang S, Zhao L, Vogt PK. Oncogenic PI3K deregulates transcription and translation. *Nat Rev Cancer*. 2005; 5(12):921–9. Epub 2005/12/13. doi: [10.1038/nrc1753](https://doi.org/10.1038/nrc1753) PMID: [16341083](https://pubmed.ncbi.nlm.nih.gov/16341083/)
49. van Riggelen J, Yetil A, Felsher DW. MYC as a regulator of ribosome biogenesis and protein synthesis. *Nat Rev Cancer*. 2010; 10(4):301–9. Epub 2010/03/25. doi: [10.1038/nrc2819](https://doi.org/10.1038/nrc2819) PMID: [20332779](https://pubmed.ncbi.nlm.nih.gov/20332779/)
50. Klijn C, Durinck S, Stawiski EW, Haverty PM, Jiang Z, Liu H, et al. A comprehensive transcriptional portrait of human cancer cell lines. *Nat Biotechnol*. 2015; 33(3):306–12. Epub 2014/12/09. doi: [10.1038/nbt.3080](https://doi.org/10.1038/nbt.3080) PMID: [25485619](https://pubmed.ncbi.nlm.nih.gov/25485619/)